Histone deacetylase
From Proteopedia
(Difference between revisions)
| Line 62: | Line 62: | ||
**[[2v5x]] - hHDAC8 (mutant) + octanediamide derivative<br /> | **[[2v5x]] - hHDAC8 (mutant) + octanediamide derivative<br /> | ||
**[[4bz5]] – SmHDAC8 – ''Schistosoma mansoni''<br /> | **[[4bz5]] – SmHDAC8 – ''Schistosoma mansoni''<br /> | ||
| - | **[[4bz7]], [[4bz8]], [[4bz9]], [[4cqf]] – SmHDAC8 + inhibitor<br /> | + | **[[4bz7]], [[4bz8]], [[4bz9]], [[4cqf]], [[6hsz]], [[6ht8]], [[6htg]], [[6hth]], [[6hti]], [[6htt]], [[6htz]], [[6hu0]], [[6hu1]], [[6hu2]], [[6hu3]], [[6hsh]], [[6hrq]], [[6hqy]] – SmHDAC8 + inhibitor<br /> |
| - | **[[4bz6]] – SmHDAC8 + SAHA<br /> | + | **[[6hsk]], [[6hsf]], [[6hsg]] – SmHDAC8 (mutant) + inhibitor<br /> |
| + | **[[4bz6]], [[6gxw]], [[6gxu]], [[6gxa]], [[6gx3]], [[6fu1]] – SmHDAC8 + SAHA derivative<br /> | ||
*'''HDAC class IIA''' | *'''HDAC class IIA''' | ||
| Line 73: | Line 74: | ||
**[[2vqw]] - hHDAC4 catalytic domain (mutant)<br /> | **[[2vqw]] - hHDAC4 catalytic domain (mutant)<br /> | ||
**[[2vqj]], [[2vqm]], [[4cbt]], [[5a2s]] – hHDAC4 catalytic domain + inhibitor<br /> | **[[2vqj]], [[2vqm]], [[4cbt]], [[5a2s]] – hHDAC4 catalytic domain + inhibitor<br /> | ||
| - | **[[2vqo]], [[2vqq]], [[2vqv]], [[4cby]] – hHDAC4 catalytic domain (mutant) + inhibitor | + | **[[6fyz]] - hHDAC4 catalytic domain + SAHA derivative<br /> |
| + | **[[2vqo]], [[2vqq]], [[2vqv]], [[4cby]] – hHDAC4 catalytic domain (mutant) + inhibitor<br /> | ||
| + | **[[5zop]], [[5zoo]] - hHDAC4 catalytic domain (mutant) + SMRT corepressor<br /> | ||
*HDAC5 | *HDAC5 | ||
| Line 108: | Line 111: | ||
**[[5kh3]], [[5kh7]], [[5kh9]], [[5b8d]], [[6ce6]], [[6ce8]], [[6cea]], [[6cec]], [[6ced]], [[6cee]], [[6cef]], [[5wpb]], [[5wbn]] – hHDAC6 zinc finger + inhibitor<br /> | **[[5kh3]], [[5kh7]], [[5kh9]], [[5b8d]], [[6ce6]], [[6ce8]], [[6cea]], [[6cec]], [[6ced]], [[6cee]], [[6cef]], [[5wpb]], [[5wbn]] – hHDAC6 zinc finger + inhibitor<br /> | ||
**[[5eem]] – zHDAC6 catalytic domain - zebrafish<br /> | **[[5eem]] – zHDAC6 catalytic domain - zebrafish<br /> | ||
| - | **[[6cgp]], [[5wgm]], [[5wgl]], [[5wgi]], [[5wgk]], [[5g0j]], [[5g0i]], [[5g0h]], [[5g0g]], [[5g0f]], [[5efh]], [[5efg]], [[5efb]], [[5ef7]], [[5ef8]], [[5een]], [[5eek]], [[5eef]] – zHDAC6 catalytic domain + inhibitor <br /> | + | **[[6cgp]], [[5wgm]], [[5wgl]], [[5wgi]], [[5wgk]], [[5g0j]], [[5g0i]], [[5g0h]], [[5g0g]], [[5g0f]], [[5efh]], [[5efg]], [[5efb]], [[5ef7]], [[5ef8]], [[5een]], [[5eek]], [[5eef]], [[6mr5]], [[6dvo]], [[6dvn]], [[6dvm]], [[6dvl]], [[6cw8]] – zHDAC6 catalytic domain + inhibitor <br /> |
| - | **[[5eei]] – zHDAC6 catalytic domain + SAHA<br /> | + | **[[5eei]], [[6css]], [[6csr]], [[6csq]], [[6csp]], [[5w5k]] – zHDAC6 catalytic domain + SAHA derivative<br /> |
**[[5efn]], [[5efk]], [[53fj]] – zHDAC6 catalytic domain (mutant) + peptide <br /> | **[[5efn]], [[5efk]], [[53fj]] – zHDAC6 catalytic domain (mutant) + peptide <br /> | ||
Revision as of 08:35, 31 July 2019
| |||||||||||
3D Structures of histone deacetylase
Updated on 31-July-2019
References
- ↑ Joshi P, Greco TM, Guise AJ, Luo Y, Yu F, Nesvizhskii AI, Cristea IM. The functional interactome landscape of the human histone deacetylase family. Mol Syst Biol. 2013;9:672. doi: 10.1038/msb.2013.26. PMID:23752268 doi:http://dx.doi.org/10.1038/msb.2013.26
- ↑ Schwer B, Verdin E. Conserved metabolic regulatory functions of sirtuins. Cell Metab. 2008 Feb;7(2):104-12. doi: 10.1016/j.cmet.2007.11.006. PMID:18249170 doi:http://dx.doi.org/10.1016/j.cmet.2007.11.006
- ↑ Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001 Dec;1(3):194-202. PMID:11902574 doi:http://dx.doi.org/10.1038/35106079
- ↑ Yamamoto H, Schoonjans K, Auwerx J. Sirtuin functions in health and disease. Mol Endocrinol. 2007 Aug;21(8):1745-55. Epub 2007 Apr 24. PMID:17456799 doi:http://dx.doi.org/10.1210/me.2007-0079
- ↑ Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007 Oct;12(10):1247-52. PMID:17962618 doi:http://dx.doi.org/10.1634/theoncologist.12-10-1247
- ↑ Jin L, Wei W, Jiang Y, Peng H, Cai J, Mao C, Dai H, Choy W, Bemis JE, Jirousek MR, Milne JC, Westphal CH, Perni RB. Crystal structures of human SIRT3 displaying substrate-induced conformational changes. J Biol Chem. 2009 Sep 4;284(36):24394-405. Epub 2009 Jun 16. PMID:19535340 doi:10.1074/jbc.M109.014928
